Luca Sardo

Dr. Luca Sardo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Viruses
Verified
Journal Article
Open access
PDF file
AMAidan McGraw
Aidan McGraw
GHGrace Hillmer
Grace Hillmer
SMStefania M. Medehincu Stefania M. Medehincu
Stefania M. Medehincu Stefania M. Medehincu
YHYuta Hikichi
Yuta Hikichi
SGSophia Gagliardi
Sophia Gagliardi
Taisuke IzumiTaisuke Izumi
Taisuke Izumi
HIV-1 virion maturation is an essential step in the viral replication cycle to produce infectious virus particles. Gag and Gag-Pol polyproteins are assembled at the plasma membrane of the virus-producer cells and bud from it to the extracellular compartment. The newly released progeny virions are initially immature and noninfectious. However, once the Gag polyprotein is cleaved by the viral protease in progeny virions, the mature capsid proteins assemble to form the fullerene core. This core, harboring two copies of viral genomic RNA, transforms the virion morphology into infectious virus particles. This morphological transformation is referred to as maturation. Virion maturation influences the distribution of the Env glycoprotein on the virion surface and induces conformational changes necessary for the subsequent interaction with the CD4 receptor. Several host factors, including proteins like cyclophilin A, metabolites such as IP6, and lipid rafts containing sphingomyelins, have been demonstrated to have an influence on virion maturation. This review article delves into the processes of virus maturation and Env glycoprotein recruitment, with an emphasis on the role of host cell factors and environmental conditions. Additionally, we discuss microscopic technologies for assessing virion maturation and the development of current antivirals specifically targeting this critical step in viral replication, offering long-acting therapeutic options.

9 February 2020 in Viruses
Verified
Journal Article
Open access
PDF file
WEWeam Elbezanti
Weam Elbezanti
ALAngel Lin
Angel Lin
ASAlexis Schirling
Alexis Schirling
AJAlexandria Jackson
Alexandria Jackson
MMMatthew Marshall
Matthew Marshall
ZKZachary Klase
Zachary Klase
Antiretroviral therapy (ART) lowers human immunodeficiency virus type 1 (HIV-1) viral load to undetectable levels, but does not eliminate the latent reservoir. One of the factors controlling the latent reservoir is transcriptional silencing of the integrated HIV-1 long terminal repeat (LTR). The molecular mechanisms that control HIV-1 transcription are not completely understood. We have previously shown that RUNX1, a host transcription factor, may play a role in the establishment and maintenance of HIV-1 latency. Prior work has demonstrated that inhibition of RUNX1 by the benzodiazepine (BDZ) Ro5-3335 synergizes with suberanilohydroxamic acid (SAHA) to activate HIV-1 transcription. In this current work, we examine the effect of RUNX1 inhibition on the chromatin state of the integrated HIV-1 LTR. Using chromatin immunoprecipitation (ChIP), we found that Ro5-3335 significantly increased the occupancy of STAT5 at the HIV-1 LTR. We also screened other BDZs for their ability to regulate HIV-1 transcription and demonstrate their ability to increase transcription and alter chromatin at the LTR without negatively affecting Tat activity. These findings shed further light on the mechanism by which RUNX proteins control HIV-1 transcription and suggest that BDZ compounds might be useful in activating HIV-1 transcription through STAT5 recruitment to the HIV-1 LTR.

1 December 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
LSLuca Sardo
Luca Sardo
CPCristina Parolin
Cristina Parolin
TYTakeshi Yoshida
Takeshi Yoshida
AGAlfredo Garzino-Demo
Alfredo Garzino-Demo
Taisuke IzumiTaisuke Izumi
Taisuke Izumi
Editorial: Novel Insights Into a Functional HIV Cure

Verified
Journal Article
Open access
PDF file
GWGuoxin Wu
Guoxin Wu
SKSamuel H. Keller
Samuel H. Keller
RWRyan Walters
Ryan Walters
YLYuan Li
Yuan Li
JKJan Kristoff
Jan Kristoff
LSLuca Sardo
Luca Sardo
Despite the success of combination antiretroviral therapy (cART) to suppress HIV replication, HIV persists in a long-lived reservoir that can give rise to rebounding viremia upon cART cessation. The translationally active reservoir consists of HIV-infected cells that continue to produce viral proteins even in the presence of cART. These active reservoir cells are implicated in the resultant viremia upon cART cessation and likely contribute to chronic immune activation in people living with HIV (PLWH) on cART. Methodologies to quantify the active reservoir are needed. Here, an automated immunocytochemistry (ICC) assay coupled with computational image analysis to detect and quantify intracellular Gag capsid protein (CA) is described (CA-ICC). For this purpose, fixed cells were deposited on microscopy slides by the cytospin technique and stained with antibodies against CA by an automated stainer, followed by slide digitization. Nuclear staining was used to count the number of cells in the specimen, and the chromogenic signal was quantified to determine the percentage of CA-positive cells. In comparative analyses, digital ELISA, qPCR, and flow cytometry were used to validate CA-ICC. The specificity and sensitivity of CA-ICC were assessed by staining a cell line that expresses CA (MOLT IIIB) alongside a control cell line (Jurkat) devoid of this marker, as well as peripheral blood mononuclear cells (PBMCs) from HIV seronegative donors before or after ex vivo infection with an HIV laboratory strain. The sensitivity of CA-ICC was further assayed by spiking MOLT IIIB cells into uninfected Jurkat cells in limiting dilutions. In those analyses, CA-ICC could detect down to 10 CA-positive cells per million with a sensitivity superior to flow cytometry. To demonstrate the application of CA-ICC in pre-clinical research, bulk PBMCs obtained from mouse and non-human primate animal models were stained to detect HIV CA and SIV p27, respectively. The level of intracellular CA quantified by CA-ICC in PBMCs obtained from animal models was associated with plasma viral loads and cell-associated CA measured by qPCR and ELISA, respectively. The application of CA-ICC to evaluate the activity of small-molecule targeted activator of cell-kill (TACK) in clinical specimens is presented. Overall, CA-ICC offers a simple imaging method for specific and sensitive detection of CA-positive cells in bulk cell preparations.

25 April 2018
Verified
Dataset
Closed access
CJChristopher Janetopoulos
Christopher Janetopoulos
LSLuca Sardo
Luca Sardo
A major barrier for HIV eradication is a reservoir of latently infected cells that persist during antiretroviral therapy. Latency is determined by intimate and for us still elusive interactions between HIV and the host. A great deal of knowledge about HIV latency derives from latency model cell lines broadly used in laboratories all over the planet. These tissue culture models were carefully engineered to reproduce features of latently infected cells in human subjects. These cell lines are robust, easy to handle and provide reproducible results, all characteristics required for a good model. How the different models work and how they respond to latency reversing agents is a matter of discussion in the field. For the first time, the prominent scientists who engineered the models teamed up to address these difficult and long unanswered questions. This article is unique as it presents a comprehensive comparison of HIV latency models with resting CD4 positive lymphocytes isolated from HIV infected subjects. In the experiments described, the authors challenge the cell models with a panel of known HIV latency reversing agents and present comparative data. This simple but thorough approach allows scientists to better understand the nuances of HIV latency models and to make informed decisions for their experiments. I highly recommend this article to readers interested in understanding HIV latency and the reactivation strategies towards HIV eradication.

28 December 2025 in Viruses
Verified
Journal Article
Open access
PDF file
GWGuoxin Wu
Guoxin Wu
LSLuca Sardo
Luca Sardo
YLYuan Li
Yuan Li
SHSteven D. Heron
Steven D. Heron
BSBaoJen Shyong
BaoJen Shyong
BHBonnie J Howell
Bonnie J Howell
The HIV-1 envelope glycoprotein gp120 is prominently exposed on the surface of both HIV-1 virions and infected host cells, serving as a key marker of infection. gp120 plays a pivotal role in viral entry by interacting with the primary receptor, CD4, on host cells. Therapeutic strategies targeting the HIV-1 reservoir, such as anti-gp120 antibodies that trigger antibody-dependent cellular cytotoxicity (ADCC) and chimeric antigen receptor T (CAR-T) cells, rely on the presence of gp120 on the surface of infected cells to exert their effects. Consequently, accurate monitoring of gp120 expression on infected cells is essential for evaluating the pharmacological efficacy of these interventions. In this study, a sensitive, specific, and inexpensive enzyme-linked immunosorbent assay (ELISA) for quantifying HIV-1 gp120 glycoprotein was developed using a selected pair of anti-gp120 antibodies. The assay achieved a lower limit of quantitation (LLOQ) of 0.16 pM, demonstrating sensitivity comparable to that of the digital single molecule array (Simoa) platform, which exhibited a LLOQ of 0.23 pM and requires specialized instrumentation. The binding specificity of the antibodies used in the novel assay was confirmed using liquid chromatography–mass spectrometry (LC-MS), and the assay was pharmacologically validated with lysates obtained from 2D10 and MOLT IIIB cell lines. Furthermore, treatment of HIV-infected human primary CD4+ T cells with a targeted activator of cell kill (TACK) compound significantly reduced gp120 concentration in CD4+ T cell lysate compared to controls. The gp120 marker from infected cell lysates correlated with the number of gp120-positive cells detected by immunocytochemistry, as well as with HIV-1 p24 levels and cell-associated viral RNA measurements. In summary, a novel, simple, and sensitive HIV-1 gp120 ELISA has been developed and validated. This assay holds potential for investigating HIV-1 persistence and evaluating the efficacy of therapeutic agents targeting infected cells.